Table 3.
Summary of echocardiographic and telemetry measurements following doxorubicin treatment in cynomolgus monkey.
| Day of study | |||||||
|---|---|---|---|---|---|---|---|
| Parameter | Treatment | 0 | 15-18 | 36-39 | 56-63 | 91-92 | Final |
| Ejection fraction | Vehicle | 0.82 ± 0.08 | 0.79 ± 0.04 | 0.82 ± 0.05 | 0.80 ± 0.06 | 0.82 ± 0.05 | 0.80 ± 0.06 |
| Doxorubicin | 0.84 ± 0.07 | 0.80 ± 0.05 | 0.79 ± 0.10 | 0.76 ± 0.06 | 0.67 ± 0.16* | 0.48 ± 0.12 | |
| Fractional shortening | Vehicle | 0.42 ± 0.08 | 0.38 ± 0.04 | 0.41 ± 0.05 | 0.39 ± 0.06 | 0.40 ± 0.06 | 0.39 ± 0.06 |
| Doxorubicin | 0.43 ± 0.07 | 0.39 ± 0.05 | 0.39 ± 0.09 | 0.35 ± 0.05* | 0.30 ± 0.11* | 0.18 ± 0.06 | |
| LVDs (cm) | Vehicle | 1.04 ± 0.19 | 1.09 ± 0.14 | 1.08 ± 0.13 | 1.14 ± 0.17 | 1.11 ± 0.19 | 1.15 ± 0.18 |
| Doxorubicin | 0.98 ± 0.20 | 1.10 ± 0.19 | 1.13 ± 0.21 | 1.20 ± 0.20 | 1.39 ± 0.37 | 1.64 ± 0.25 | |
| LV contractility (dP/dtmax) | Vehicle | 2,309 ± 477 | 2,859 ± 872 | 2,815 ± 816 | 3,304 ± 1,019 | 2,866 ± 955 | 2,746 ± 693 |
| Doxorubicin | 2,710 ± 894 | 2,368 ± 702 | 2,531 ± 745 | 2,706 ± 923 | 2,088 ± 417 | 1,812 ± 360 | |
| QTc (msec) | Vehicle | 276 ± 27 | 277 ± 29 | 276 ± 25 | 269 ± 25 | 267 ± 28 | 271 ± 25 |
| Doxorubicin | 299 ± 26 | 324 ± 25* | 321 ± 26* | 313 ± 27* | 331 ± 32* | 350 ± 49 | |
| Heart rate (bpm) | Vehicle | 106 ± 11 | 120 ± 23 | 116 ± 19 | 114 ± 19 | 115 ± 21 | 111 ± 19 |
| Doxorubicin | 112 ± 17 | 113 ± 17 | 121 ± 17 | 115 ± 20 | 133 ± 25 | 138 ± 28 | |
| Mean BP (mm Hg) | Vehicle | 70 ± 12 | 76 ± 13 | 76 ± 14 | 76 ± 13 | 73 ± 13 | 75 ± 15 |
| Doxorubicin | 76 ± 13 | 77 ± 15 | 77 ± 16 | 75 ± 17 | 69 ± 18* | 66 ± 20 | |
All values are means ± SD (N = 12). Final = last available measurement prior to scheduled or unscheduled sacrifice.
*
Statistically different from vehicle treated animals (p < 0.05). As Final was on different days for different animals, no statistical assessment is denoted.